ChauTDangMD

Assistant Professor, Medicine, Weill Cornell Medical College

Overview of Dr. Dang

Dr. Chau Dang is an oncologist in West Harrison, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, NYC Health + Hospitals / Bellevue, Phelps Memorial Hospital Center, and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from Medical University of South Carolina College of Medicine and has been in practice 25 years. Dr. Dang accepts several types of health insurance, listed below. She is one of 495 doctors at Memorial Sloan Kettering Cancer Center and one of 62 doctors at NYC Health + Hospitals / Bellevue who specialize in Oncology. She has more than 100 publications and over 500 citings.

Office
500 Westchester Avenue
West Harrison, NY 10604
Book by Phone+1(773) 569-3576

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1996 - 1999
Allegheny Health Network Medical Education Consortium (AGH)Residency, Internal Medicine, 1993 - 1996
Eastern Virginia Medical SchoolInternship, Transitional Year, 1992 - 1993
Medical University of South CarolinaClass of 1992

Certifications & Licensure

FL State Medical License 2021 - Present
NJ State Medical License 2019 - 2025
NY State Medical License 1996 - 2025
PA State Medical License 1994 - 1996

Clinical Trials

Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer Start of enrollment: 2000 Jun 01
Completed
Phase 2
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer Start of enrollment: 2007 Nov 02
Active, not recruiting
Phase 3
Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer Start of enrollment: 2007 Mar 01
Completed
Phase 2
Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility Start of enrollment: 2004 Dec 01
Completed
Phase 2
Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility Start of enrollment: 2004 Nov 01
Completed
Not Applicable
Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer Start of enrollment: 2011 Jan 05
Completed
Phase 2
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer Start of enrollment: 2012 Dec 11
Completed
Phase 2
Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 2
Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy Start of enrollment: 2015 Jan 12
Active, not recruiting
Phase 2
Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer Start of enrollment: 2017 Dec 13
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

30 citations
SAFE‐HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2‐Positive Breast Cancer and Reduced Left V...
Filipa Lynce, Ana Barac, Ming Tan, Federico M. Asch, Karen L. Smith
The Oncologist. 2017-05-01
19 citations
Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compr...
Katia E. Khoury, Filipa Lynce, Ana Barac, Xue Geng, Chau T. Dang
Breast Cancer Research and Treatment. 2021-01-05
30 citations
Racial and Socioeconomic Disparities in Cardiotoxicity Among Women With HER2-Positive Breast Cancer.
Mohammed Al-Sadawi, Yasin Hussain, Robert S. Copeland-Halperin, Jonathan N. Tobin, Chaya S. Moskowitz
The American Journal of Cardiology. 2021-02-20

Journal Articles

Left Ventricular Ejection Fraction Monitoring Adherence Rates
Chau T Dang, Sandra M Swain, Anne Blaes, ScienceDirect

Press Mentions

Impressive Disease Control in Metastatic Triple-Negative Breast CancerMay 14th, 2021
Emerging Cardio-Oncology Field Fights Heart Disease in Breast Cancer PatientsOctober 30th, 2019
PCI in Cancer; Beta-Blocker Prophylaxis; Stress Echo Predicts Cancer DeathsDecember 10th, 2018
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment